Abstract: Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as neo-adjuvant treatment has been estimated in clinical trials of advanced breast cancer. To date, the overall observed clinical improvements are unconvincing, and further research is required to demonstrate the efficacy of anti-angiogenic drugs in breast cancer treatments. The outcomes of anti-angiogenic therapy have been highly variable in terms of tumor response. New methods are needed to identify patients who will benefit from this regimen. The development of biomarkers and molecular profiling are relevant research areas.
that may strengthen the ability to focus anti-angiogenic therapy towards suitable patients, thereby increase the cost-effectiveness, currently estimated to be inadequate.

**Keywords:** breast cancer; anti-angiogenic therapy; biomarkers; vascular endothelial growth factor

### 1. Introduction

Breast cancer is the second most common cancer worldwide with an estimate of 1.7 million diagnosed cases in 2012 [1]. Since 2008, there has been a marked increase in breast cancer by more than 20% [1]. The survival of the patients suffering from breast cancer is strongly associated with prognostic factors, including tumor size, hormone-receptor-profile and existence of metastases. The primary treatment of breast cancer is surgical removal of the tumor, either as a lumpectomy or a mastectomy. Preoperative analyses of tumor size and possible metastases to the sentinel lymph node are decisive for the choice of surgery and the following treatment. Adjuvant therapies, such as chemotherapy, radiation and anti-hormone therapy, targeted treatment against human epidermal growth receptor 2 (HER2) and anti-angiogenic therapy can be applied postoperatively or, in the case of advanced disease stages, when surgery is no longer an option [2,3]. It is estimated that 50% of breast cancer patients are fully cured by surgical removal of the tumor, and another 25% are cured by surgical resection followed by postoperative systemic chemotherapy. At the moment, trials are also investigating the effect of neo-adjuvant treatment of breast cancer to minimize spread and improve the conditions for curative surgical tumor removal [4,5]. Sufficient oxygen and nutrition supply is essential for tumor growth. To support tumor growth, a rapid increase in the formation of blood vessels is required. Tumor angiogenesis is a multistep process requiring signaling between tumor cells and several cell types within the tumor microenvironment. This leads to overexpression of pro-angiogenic factors by the tumor, such as vascular endothelial growth factor (VEGF), referred to as the “angiogenic switch” [6].

High levels of circulating VEGF are a well-established indicator of poor prognosis [7]. The VEGF family consists of several signal protein variants and their receptors. Among them, the VEGF-A and VEGF receptor (VEGFR) subtype 2 interaction is the predominant interaction in angiogenesis [8]. One of the main regulators of the VEGF expression is oxygen tension. Hypoxic conditions observed in the interior of solid tumors activates hypoxia inducible factor (HIF), which initiates the transcription of various cytokines, including VEGF, which is a potent endothelial mitogen and pro-angiogenic factor [6]. Tumor vasculature shows abnormal features being twisted, heterogeneous, irregular lumen and exhibit atypical branching. The pericytes and basement membranes are abnormal, as well [8], and high turnover of vessels, reduced perfusion and increased leakage are observed [9]. Anti-angiogenic therapy inhibits tumor vessel growth by interfering with the intracellular signaling of VEGF and VEGFR [9–11].
2. Anti-Angiogenic Therapy

2.1. Angiogenesis

2.1.1. Definition of Angiogenesis

Angiogenesis has been used as a term since 1935. It was first introduced to describe the formation of new blood vessels in the placenta, but later, the term included the formation of new vessels in wound healing and in tumor growth, as well. In 1971, Judah Folkman hypothesized that targeting angiogenesis might be useful in treating cancer [12].

2.1.2. Spouting, Intussusception, Vascular Mimicry, Vascular Co-Option and Regulation of These Processes

There are several modes of vessel formation. In the embryo, the de novo generation of blood vessels originates from a mesoderm-derived hemangioblast, a common stage in the development of endothelial cells (EC) and blood cells, which differentiate into angioblasts that come together to form a vascular labyrinth in a process called vasculogenesis [11]. Angiogenesis, the development of new blood vessels, is important in cancer development, since tumor growth is dependent on the sufficient supply of oxygen and nutrients. The diffusion from capillaries is unable to go beyond 100–200 μm; therefore, in order to sustain cell function and to survive, the tumor must recruit new vessels [13]. ECs have oxygen sensors and hypoxia-inducible factors. This gives the ECs the ability to adjust their shape [8]. Endothelial sprouting is the main mechanism of tumor angiogenesis. This process, which involves ECs, pericytes, stroma cells and the extracellular matrix (ECM), depends on the upregulation of vascular endothelial growth factors [6]. There are several pathways that regulate endothelial cell migration. VEGF has been shown to regulate the release of matrix metalloproteinases (MMPs) and urokinase plasminogen activators, both damaging the basal membrane and the extracellular matrix. It allows EC migration and sprouting [9]. During the sprouting process, specialized ECs take the lead in the formation of the sprouting vessel. This cell is called the tip cell. The tip cell guides the vessel towards the tumor with its hypoxic, avascular region. It is followed by a so-called stalk cell, which divides to elongate the sprouting vessel. The tip cells express VEGFR-2 and Delta-like ligand 4, which binds to NOTCH receptors on the stalk cells. This interaction downregulates the expression of VEGFR-2 on the stalk cells, which allows the tip cells to continue leading the sprout, while the stalk cells proliferate and form the lumen of the vessel [8]. After stabilization of the vessel walls, the cells become non-proliferating cells, called phalanx cells. These cells are interconnected by the molecules, VE-cadherin and claudins, which strengthen the vessel wall and create a permeability barrier. The phalanx cells also regulate blood flow and perfusion of the vessels and recruit pericytes and smooth muscle cells by producing platelet-derived growth factor-b. These smooth muscle cells cover the naked vessels for further stabilization of the new vessels [11]. Pericytes produce factors that suppress endothelial proliferation and promote cell survival, such as VEGF and ANG-1 [8]. Tumor vessels can grow in several other ways than sprouting, among them intussusception and vasculogenic mimicry. Intussusception is a process in which the vessel wall is stretched into the lumen and then splits the vessel into two. Vasculogenic mimicry is a process in which the tumor cells alter their gene expression patterns to switch to a more undifferentiated phenotype that allows them
to line vessels themselves. The vasculogenic mimicry seems to be independent of some pro-angiogenic factors, such as VEGF, and therefore, anti-angiogenic therapies do not always inhibit the process [11]. The formation of new vessels for tumor growth and metastasis plays a key role in cancer research and in the development of new drugs targeting angiogenesis. However, blood supply may be obtained by vessel co-option, the use of existing vessels, without triggering angiogenesis [14]. The mechanism was so far mostly reported in highly vascularized tissues, such as brain, lung and liver [15]. Donnem et al. [15] published that in primary and metastatic lung cancer and liver metastasis from different primary origins, as much as 10%–30% of the tumors use this alternative blood supply. This mechanism offers a potential explanation for angiogenic drug resistance observed in anti-angiogenic therapy, although the impact of vessel co-option requires further research.

2.2. Vascular Endothelial Growth Factor (VEGF) Family

VEGF is a very important factor involved in angiogenesis. The VEGF family includes eight members; VEGF-A (also referred to as VEGF), VEGF-B, VEGF-C, VEGF-E, VEGF-F, placental growth factor (PLGF)-1 and PLGF-2 [13]. The factors bind with different affinity and specificity to three tyrosine kinase receptors; vascular endothelial growth factor receptor VEGFR-1, VEGFR-2 (also known as FLK1) and VEGFR-3 (Figure 1). Vascular endothelial cells mainly express VEGFR-1 (binds VEGF-A, VEGF-B and PlGF) and VEGFR-2 (binds predominantly VEGF-A). VEGFR-3 is mainly found on lymphatic ECs and regulates the lymph-angiogenesis [10,16,17]. When binding to one receptor, the VEGFs stimulate dimerization of the receptor and initiate a signaling cascade that promotes ECs survival, growth and migration [18]. Furthermore, vessel permeability and endothelial progenitor cells are also stimulated. VEGF-A is the key factor in angiogenesis and primarily stimulates VEGFR-2 [13]. VEGF-A is also important in several physiological processes, including menstruation, ovulation, pregnancy, wound healing and maintenance of blood pressure [19–22]. It is a dimeric disulfide-bound glycoprotein that, due to splicing and posttranslational processing, can be composed of amino acid chains of various lengths. The most common isoform contains 165 amino acids and is overexpressed in several different human tumors [13,23]. In tumors, VEGF is produced by a variety of cells, including the tumor cells, the ECs and infiltrating myeloid cells. The interaction between the VEGF and its receptor will affect the EC in several different ways and will result in EC proliferation, migration, vascular permeability and invasion into the surrounding tissue and endothelial inflammation [9]. The main regulator of VEGF expression is oxygen tension. Under non-hypoxic conditions, the prolyl hydroxylase domain (PHD) protein hydroxylates HIF. When hydroxylated, HIF is recognized by the von Hippel-Lindau tumor suppressor (VHL) and is destroyed by proteases. In hypoxic conditions, like during tumor growth, the PHD is inactive, which hinders degradation, and HIF translocates to the nucleus and initiates transcription of various genes, among them VEGF, platelet-derived growth factor (PDGF) and MMP-1. In the sprouting process, the VEGF induces both NOTCH-mediated proliferation in the stalk cells and hypoxic migration cues to the tip cell [6].
3. Overview of Anti-Angiogenic Drugs Targeting the VEGF System

There are three major targets and groups of drugs available for anti-VEGF therapy: drugs interfering with the VEGF ligand, drugs interfering with the VEGFRs and drugs interfering with intracellular signaling of the VEGFRs [10,24]. Bevacizumab and ramucirumab are monoclonal humanized antibodies designed to inhibit the interaction between VEGF ligands and receptors [25,26], whereas sorafenib is a tyrosine kinase inhibitor (TKI) targeting VEGFRs, but also with an affinity for other tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) [27]. An overview of the results from clinical trials of breast cancer using the anti-angiogenic drugs discussed in this review is given in Table 1. Furthermore, Figure 2 shows a schematic representation of the modes of action of these drugs.

Figure 1. Overview of VEGF variants and their receptors. VEGFR, vascular endothelial growth factor (VEGF) receptor; PlGF-1/2, placental growth factor-1/2; NRP-1/2, Neuropilin-1/2.
Table 1. Overview of results of trials using bevacizumab, sorafenib and ramucirumab. For bevacizumab and sorafenib, progression-free survival (PFS), overall response rate (ORR), pathological complete response (pCR) and overall survival (OS) denote the effect of treatment with bevacizumab/sorafenib vs. without. NS, no significant improvement.

| Drug         | Trial/Reference | Treatment       | Drugs Used                                      | PFS    | ORR   | pCR   | OS     |
|--------------|-----------------|-----------------|------------------------------------------------|--------|-------|-------|--------|
| bevacizumab  | AVF2119g        | Second-line     | Capecitabine +/- bevacizumab                    | NS     | Significant | Not reported | NS    |
| bevacizumab  | ECOG-E2100      | First-line      | Paclitaxel +/- bevacizumab                      | Significant | Significant | Not reported | NS    |
| bevacizumab  | AVADO           | First-line      | Docetaxel +/- bevacizumab (arm treated with highest dosage bevacizumab) | Significant | Significant | Not reported | NS    |
| bevacizumab  | RIBBON-1        | First-line      | Capecitabine/taxane/ Anthracycline based chemotherapy +/- bevacizumab | Significant | Significant | Not reported | NS    |
| bevacizumab  | RIBBON-2        | Second-line     | Capecitabine/taxane/ gemcitabine/vinorelbine based chemotherapy +/- bevacizumab | Significant | Significant | Not reported | NS    |
| bevacizumab  | GBG44/clinicaltrials.gov ID: NCT00567554 | Neoadjuvant therapy | Epirubicin/cyclophosphamide/docetaxel +/- bevacizumab | Not reported | Not reported | Significant | Data under way |
| bevacizumab  | NSABP           | Neoadjuvant therapy | Docetaxel/capecitabine/gemcitabine +/- bevacizumab | Not reported | Not reported | Significant | Data under way |
| bevacizumab  | AVEREL          | First-line      | Trastuzumab/docetaxel +/- bevacizumab           | NS     | NS    | Not reported | NS    |
| sorafenib    | SOLT0701        | First-line/second-line | Capecitabine +/- sorafenib                     | Significant | NS    | -     | NS    |
| sorafenib    | AB01B07         | Second-line     | Capecitabine and gemcitabine +/- sorafenib     | Significant | NS    | -     | NS    |
| sorafenib    | NU07B1          | First-line      | Paclitaxel +/- sorafenib                       | NS     | Significant | -     | NS    |
| sorafenib    | FMB0701         | First-line      | Docetaxel and/or letrozole +/- sorafenib       | NS     | NS    | -     | NS    |
| ramucirumab  | TRIO-012        | -               | Docetaxel +/- ramucirumab                      | NS     | NS    | -     | NS at interim analysis |
| ramucirumab  | clinicaltrials.gov ID: NCT01427933 | Second-line | Eribulin +/- ramucirumab                       | Not reported | Not reported | Not reported | Not reported |
Figure 2. Overview of bevacizumab, ramucirumab and sorafenib and their inhibition of targets in anti-angiogenic treatment. VEGFR2, vascular endothelial growth factor (VEGF) receptor 2; Raf-1, proto-oncogene, serine/threonine kinase; PKC, protein kinase C; MAPK, mitogen activated protein kinase.

3.1. Bevacizumab

VEGF-A expression has been found to be upregulated in various human tumors, including breast cancer [27]. Bevacizumab is a monoclonal antibody that binds and inactivates soluble VEGF-A molecules, resulting in inhibition of VEGF-mediated angiogenesis [25]. Bevacizumab was mainly tested in combination with chemotherapeutic drugs and in the neoadjuvant therapy regimen [27,28]. These chemotherapeutics include capecitabine, paclitaxel, docetaxel, anthracyclines, gemcitabine and vinorelbine, which are approved chemotherapeutic drugs against breast cancer. The results of a variety of trials, including the randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously-treated metastatic breast cancer [25] and the trial paclitaxel plus bevacizumab vs. paclitaxel alone for metastatic breast cancer (NCT00028990) [29], led to the approval of bevacizumab as an effective drug against breast cancer by the European Medicines Agency (EMEA) in March, 2007, and by the U.S. Food and Drug Administration (FDA) in December, 2008 [30]. In 2010 through 2014, trials, such as first-line trials “Avastin and Docetaxel” (AVADO), “Regimens in Bevacizumab for Breast Oncology” (RIBBON)-1 and “Maintenance capecitabine and bevacizumab vs. bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer” (IMELDA) [31–33] and second-line trials RIBBON-2 and “Bevacizumab plus
chemotherapy vs. chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy” (TANIA) [34,35], confirmed the positive impact of bevacizumab on the endpoints of progression-free survival (PFS) and overall response rate (ORR), but also confirmed the missing impact on overall survival (OS). Furthermore, serious adverse effects were also demonstrated in these trials. As a consequence, the FDA withdrew their earlier approval of bevacizumab as an effective anti-angiogenic agent against HER2-negative metastatic breast cancer. In contrast, the EMEA maintained their approval [36].

The main results until now are that treatments with bevacizumab in combination with chemotherapy have significantly improved the endpoints of ORR, PFS and pathological complete response (pCR) vs. patients treated with chemotherapy plus placebo. According to the AVADO trial, bevacizumab improved efficacy, including one-year OS rates (71% vs. 65%). The PFS was 8.1 months with bevacizumab vs. 5.4 months with chemotherapy alone [31]. Several earlier trials showed a prolonged PFS (Table 1). Two trials did not show improved ORR and PFS; the AVF2119g trial demonstrated an insignificant effect on the endpoint of PFS after adding bevacizumab to capecitabine as a second line treatment of metastatic breast cancer. Furthermore, the hazards ratio for investigator-assessed PFS in the AVEREL trial of HER2-positive metastatic breast cancer patients was not significantly affected (0.82; 95% CI: 0.65 to 1.02; \( p = 0.0775 \)) [37]. Median OS exceeded 38 months in both arms. There was no difference between the treatment arms in OS [37]. Positive results for PFS and OS were found in the IMELDA trial [33]. In the ongoing TANIA (clinicaltrials.gov ID: NCT01250379) trial [35], the magnitude of improvement in progression-free survival (stratified HR 0.75, 95% CI: 0.61–0.93; log-rank \( p = 0.0068 \)) is very similar to that noted in the RIBBON-2 trial. Continuous second-line combination treatment with bevacizumab and chemotherapy significantly improved PFS compared to bevacizumab, for patients with metastatic or locally-recurrent breast cancer. In addition, in the IMELDA study, OS was significantly improved, 39.0 vs. 23.7 months [33]. Adverse effects of bevacizumab include hypertension, bleeding events, proteinuria and sensory neuropathy [38]. In many cases toxicity or progression of disease forced patients to discontinue therapy. The subpopulations of patients discontinuing therapy were higher for those patient groups treated with bevacizumab vs. placebo treatment patient groups [30]. Currently ongoing trials of bevacizumab in the therapy of breast cancer are listed in Table 2.

3.2. Ramucirumab

Ramucirumab is a humanized monoclonal antibody against the VEGF-binding domain of the VEGFR-2, which is found to be overexpressed in many human breast cancers and seems be an important receptor facilitating VEGF-mediated angiogenesis [38]. Ramucirumab binds to VEGF-2 with strong affinity and inhibits interaction between tumor-produced VEGF and VEGFR-2 [39]. A phase I study from 2010 examined the effect of ramucirumab against different malignant tumors and revealed promising data for ramucirumab in anti-angiogenic therapy. Keeping in mind that the study population was relatively small and heterogeneous, ramucirumab decreased tumor perfusion and vascularity in 69% of evaluable patients [39]. Adverse effects associated with ramucirumab are similar to those for bevacizumab [26]. At the moment, a phase III trial on ramucirumab in combination with chemotherapy is ongoing [40]. The trial started in 2009 and recruited patients with yet untreated HER2-negative metastatic breast cancer. The patients are randomized to receive docetaxel plus ramucirumab vs.
docetaxel plus placebo in three-week-cycles throughout the follow-up period. The study will be published in December 2015, and will reveal the potential effects of ramucirumab in combination with docetaxel for first-line treatment of HER2-negative metastatic breast cancer. A phase II open-label study of 141 unresectable patients randomized to receive eribulin monotherapy or eribulin plus ramucirumab in three-week cycles was completed in September 2013. Results of both safety and efficacy await publication (clinicaltrials.gov ID: NCT01427933).

Table 2. Current protocols studying bevacizumab intervention in breast cancer. The table is based on studies registered at ClinicalTrial.gov. [41] and specific search criteria: phase I–IV, open studies, exclude unknown status, interventional studies. Condition: breast cancer.

| Protocol Title                                                                 | Phase | Condition                                                                 | Intervention                                                                 | Clinicaltrials.gov     |
|-------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------|
| Patient Preference for Everolimus in Combination with Exemestane or Capecitabine in Combination with Bevacizumab (IMPROVE) | IV    | Advanced (Inoperable or Metastatic) HER2-negative Hormone Receptor Positive Breast Cancer | Everolimus + Exemestane vs. Capecitabine + Bevacizumab                         | NCT02248571            |
| Trastuzumab or Bevacizumab with Combination Chemotherapy in Treating Patients with Stage II–III Breast Cancer | II    | Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer | Trastuzumab vs. Bevacizumab + Chemotherapy (Docetaxel; Carboplatin; Doxorubicin Hydrochloride; Cyclophosphamide, Paclitaxel) | NCT01959490            |
| Bevacizumab in Combination with Chemotherapy in the Neo-adjuvant Setting for HER2 (−) Breast Cancer | II    | Breast Cancer                                                             | Neoadjuvant Treatment of Bevacizumab + Chemotherapy (5-Fluorouracil, Epirubicin; Cyclophosphamide; Docetaxel) | NCT01985841            |
| Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer with Brain Metastases | II    | Breast Cancer; Brain Metastases                                           | BEEP (bevacizumab preconditioning followed by etoposide and cisplatin) Regimen Prior to Radiotherapy | NCT02185352            |
| Safety and Efficacy Study of Eribulin in Combination with Bevacizumab for Second-line Treatment HER2-MBC Patients (GIM11-BERGI) | II    | Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Bevacizumab and Eribulin                                                     | NCT02175446            |
| Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer | I     | Pleural Effusion, Malignant; Breast Cancer                                | Bevacizumab                                                                 | NCT02250118            |
Table 2. Cont.

| Protocol Title                                                                 | Phase | Condition                                                                 | Intervention                                                                                     | Clinicaltrials.gov   |
|-------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------|
| Bevacizumab Plus Paclitaxel Optimization Study with Interventional Maintenance | II    | Metastatic Breast Cancer                                                   | Weekly Paclitaxel + Bevacizumab vs. Weekly Paclitaxel + Bevacizumab                               | NCT01989780          |
| Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer (BOOSTER) |       |                                                                            | Followed By Hormone Therapy + Bevacizumab Then back to Weekly Paclitaxel + Bevacizumab             |                      |
|                                                                                   | II    | Breast Cancer                                                              | Carboplatin/Cyclophosphamide vs. Carboplatin/Cyclophosphamide + Bevacizumab vs. Paclitaxel + Bevacizumab | NCT01898117          |
|                                                                                   |       |                                                                            | vs. Paclitaxel + Bevacizumab                                                                  |                      |
|                                                                                   | I     | Breast Cancer; Ovarian Cancer; Gynecological Cancer; Head and Neck Carcinoma; Non-Small-Cell-Lung Cancer; Small-Cell-Lung Cancer; Non-Squamous-Cell-Lung Cancer | PM01183 + Paclitaxel vs. PM01183 + Paclitaxel + Bevacizumab                                    | NCT01831089          |

3.3. Sorafenib

Sorafenib is a tyrosine kinase inhibitor and exerts an anti-proliferative and anti-angiogenic activity by blocking the intracellular signal transduction of VEGFR-2 in endothelial cells. Monotherapy using sorafenib has not shown significant results in breast cancer [42]. Some trials suggest that due to the fact that sorafenib targets angiogenesis at multiple steps, the agent may be able to affect the pathways involved in the case of bevacizumab-resistance. This theory was tested by applying sorafenib to second-line treatments of chemotherapy to patients who had failed therapy with bevacizumab. The results of the trial demonstrated a significant prolongation in PFS, when sorafenib was added to gemcitabine/capecitabine [43]. Four relevant phase II trials, known as the Trials to Investigate the Efficacy of Sorafenib (TIES) have tested the effect of sorafenib in patients with HER2-negative advanced or metastatic breast cancer [42]. The common conclusion of the trials is that sorafenib has anti-tumor activity and improves PFS and ORR, when it is applied in combination with certain chemotherapeutic drugs. None of the trials demonstrated a beneficial impact of sorafenib on OS [42]. Multiple adverse effects have been observed with protein kinase inhibitors and involve almost every organ of the body. Most frequent adverse effects are hypertension, anemia, rash, neutropenia, thrombocytopenia, fever, infections and fatigue. Further trials are needed to assess the beneficial anti-angiogenic effects of sorafenib. A phase III trial on capecitabine +/- sorafenib was initiated.
in 2010. The primary endpoint will be PFS, and secondary focuses will be the improvements of tolerability by dosage adjustments and the search for potential biomarkers [42].

3.4. Adverse Effects

The dosage of anti-cancer therapy is limited by its adverse effects and is usually not adjusted according to the lowest dose of the therapeutic window, as is the case in most other pharmacologic therapy [44]. Generally observed adverse effects, in relation to anti-angiogenic therapy, are hypertension, congestive heart failure, proteinuria caused by renal failure, bone marrow depression, rash and sensory neuropathy. A recent retrospective analysis has estimated a prevalence of 38% of bevacizumab-induced hypertension in breast cancer patients. Furthermore, the study suggested that development of hypertension during treatment might be a marker for the effect of bevacizumab [45].

4. Biomarkers

Biomarkers are able to define the subpopulation of breast cancer patients that benefits from anti-angiogenic therapy and makes it possible to target treatment therapies towards susceptible patients, which will increase the efficacy of anti-angiogenic therapy [46]. Especially, biomarkers related to treatment with bevacizumab have been intensively investigated. The most debated possible biomarkers involve HER2-receptor status, polymorphisms in genes, such as BRCA1/2, TP53 and PTEN [47–49], the level of plasma-VEGF-A and, recently, hypertension. The outcomes of research on HER2-receptor status are inconclusive. First, an exploratory subgroup analysis of the RIBBON-2 trial demonstrated a higher improvement of PFS in triple-negative breast cancer (TNBC) patients suggesting that TNBC and HER2-negative patients have the strongest benefit of bevacizumab treatment [34]. Correlation between the prognosis of anti-angiogenic therapy and HER2/estrogen receptor status has yet to be shown. In a retrospective study on the data of Eastern Cooperative Oncology Group (ECOG)-E2100 [29], specific single-nucleotide polymorphisms (SNPs) in genes of VEGF were identified that could be used to identify the subgroups of patients being most receptive for anti-angiogenic therapy [50]. However, no correlation between the SNP and PFS was eventually found [34]. In contrast, data on the circulating VEGF-A as a biomarker are more consistent, associating high baseline levels of plasma VEGF-A to a stronger effect of bevacizumab treatment. These data are supported by findings in the AVEREL [37] and the AVADO trial [31,51,52]. The data of AVEREL revealed that a high plasma concentration of VEGF-A at baseline was associated with a poorer prognosis, independent of the type of treatment. Moreover, the AVEREL study indicated that treatment with bevacizumab is more efficient in patients with high baseline VEGF-A concentrations than in patients with low VEGF-A concentrations, HR 0.70 vs. 0.83. \( p = 0.80 \) [37]. The same observations were found in the data of AVADO, in which the study populations were divided into four quartiles according to VEGF-A concentrations. The outcome showed non-significant improved hazard ratios with increasing VEGF-A-baseline levels [52]. Importantly, none of the described results were statistically significant, and future trials are required to investigate the role of VEGF-A plasma levels as a clinical predictor of outcomes in bevacizumab treatment [37]. To address these issues, a prospective trial focusing on the role of VEGF-A as a biomarker has recently started recruitment (clinicaltrials.gov ID: NCT01663727). The patients will be stratified according to their baseline levels.
of plasma VEGF-A before randomization to treatment of paclitaxel plus bevacizumab and paclitaxel plus placebo, respectively.

As briefly mentioned above, the development of hypertension during bevacizumab treatment has recently been demonstrated to be associated with an improved response. This statement emerges from a new retrospective study by Gampenrieder et al. [45] that shows that breast cancer patients developing hypertension during treatment had a more favorable outcome of PFS and two-year OS. Both results were significant: PFS 13.7 vs. 6.6 month, HR = 0.34, 95% CI = 0.23–0.49, p < 0.001, and two-year OS 78% vs. 30%, HR = 0.20, 95% CI = 0.12–0.35, p < 0.001 [45]. The population used in this analysis was heterogeneous, and hypertension is indeed not a desired effect of bevacizumab treatment. Nonetheless, this side effect of bevacizumab was associated with more favorable outcomes of anti-angiogenic therapy. A study by Keyhani et al. [53] focused on estimating the rate of angiogenesis in different breast cancer patient groups. The rationale for the analysis is that by defining which breast cancer patient groups have the biggest rate of angiogenesis, one can define which patients will benefit the most from angiogenic therapy. The study reported a correlation between tumor stage and simultaneous mutation of HER2 and TP53, as well as a correlation between micro-vessel density and patient’s age and concluded that patients younger than 50 years had a higher rate of angiogenesis. Finally, neuropilin-1 and VEGFR-3 expression have also been evaluated as potential biomarkers. According to a few data of AVF2119g, low expression on neuropilin-1 seems to be associated with increased clinical benefits of bevacizumab [54]. Similar findings exist in trials of bevacizumab in gastric cancer and colorectal cancer [55,56]. In contrast, the AVADO trial showed inconsistent results regarding levels of neuropilin-1. High baseline levels of VEGFR-2 have demonstrated a more favorable outcome of bevacizumab than low baseline levels of VEGFR-2, but the difference in outcome was not significant [54]. In the case of more indications of a predictive role of VEGFR-2 expression, more trials focusing on VEGFR-2 as a biomarker would be relevant. To sum up, many different factors have been evaluated as biomarkers: HER2 status, genetic polymorphisms, plasma levels of VEGF-A, hypertension and age of patients. More research in this area is highly relevant, because patient benefits and the cost-effectiveness of anti-angiogenic drugs depend on the ability to target and monitor patients who will show the strongest response to anti-angiogenic therapy.

5. Conclusions and Future Developments

Anti-angiogenic agents impact and reduce the growth of malignant breast tumors. Until now, the use of agents targeting VEGF-driven angiogenesis in combination with standard protocols or in neoadjuvant therapy have shown modest clinical efficacy. Several contributing factors may explain the low efficacies obtained so far, including drug resistance, alternative triggers of angiogenesis, vessel co-option and the problem of identifying who will benefit from anti-VEGF therapy in breast cancer. However, the impact for angiogenic therapies in improving clinical outcomes is not yet clearly evaluated, but results from the TANIA and IMELDA trials published in 2014 [33,35] showed that continued second-line treatment with bevacizumab plus chemotherapy significantly improved PFS compared to bevacizumab alone, suggesting an improved efficacy of sustained anti-angiogenic treatment.

Furthermore, the IMELDA trial data suggest that an early switch to maintenance therapy might be beneficial, challenging the current treatment paradigms for HER2-negative metastatic breast cancer [57].
Breast cancers are heterogeneous in nature, which may account for much of the clinical variability observed from anti-angiogenic therapies. As these therapies are targeted towards specific signaling pathways, clinical success is highly dependent on *a priori* knowledge of the tumor responsiveness. Development of reliable biomarkers to identify which patients are likely to match the target pathology and to respond to anti-angiogenic therapy is a key factor. Molecular-based standards for evaluating a therapeutic index on an individualized basis before treatment with anti-angiogenic drugs may increase the efficacy substantially. To achieve this aim, translational research using genomic and proteomic technologies may be applied to samples of past and ongoing clinical trials to provide molecular signatures and formal sub-classification of tumors [58] that may help select/deselect appropriate treatments. Moreover, such research may also identify new target molecules and biomarkers and provide useful knowledge for designing future clinical trials. A promising candidate for future trials may be ellagic acid, which is shown to reduce VEGF-related processes significantly. Ellagic acid inhibits both VEGFR-2 and intracellular pathways and may be able to inhibit the growth of breast cancers [59]. Future therapeutic strategies utilizing multiple markers, from several sources, may help to predict the benefits of anti-angiogenic therapy more robustly than single-biomarker approaches [60].

Another aspect is that VEGF plays also an important immunological role [61]. It has been shown *in vitro* that mesenchymal stem cell-secreted IL-6 and VEGF may act as paracrine factors to sustain breast cancer cell migration [62]. In addition, it is known that programmed death-ligand 1 (PD-L1), which is expressed by endothelial cells, plays a key role in suppressing the immune system. Anti-PD-L1 together with anti-VEGF therapies are now being tested in clinical trials [61]. The future will show whether this combined approach has beneficial effects on the PFS and OS in breast cancer patients.

**Author Contributions**

Tina Bøgelund Kristensen and Malin L. T. Knutsson contributed equally to this manuscript. They compiled the data and prepared the first draft of the manuscript. Elisabeth Warnke produced the figures. Nils E. Magnusson wrote the chapter on biomarkers and the chapter on conclusions and future developments and was involved with the editing of the manuscript, together with Daniela Grimm, Markus Wehland and Britt Elmedal Laursen.

**Abbreviation**

EC, Endothelial cell; ECM, Extracellular matrix; EMEA, European Medicines Agency; FDA, Food and Drug Administration; HER2, Human epidermal growth receptor 2; HER2-positive, Tumor shows overexpression of HER2-receptors; HER2-negative, Tumor does not show overexpression of HER2-receptors; HIF, Hypoxia induced factor; MAPK, Mitogen activated protein kinase; MMP, Matrix metalloproteinases; NPLD, Non-PEGylated liposome-encapsulated doxorubicin; ORR, Overall response rate; OS, Overall survival; pCR, Pathological complete response; PDGFB, Platelet-derived growth factor-b; PFS, Progression-free survival; PHD, Prolyl hydroxylase domain; PKC, Protein kinase C; PLGF-1/-2, Placental growth factor-1/-2; Raf-1, Proto-oncogene, serine/threonine kinase; SNP, Single nucleotide polymorphism; TIES, Trials to Investigate the Efficacy of Sorafenib; TNBC, Triple negative breast cancer: the tumor is HER2-negative, ER-negative and PR-negative; VEGF, Vascular endothelial
growth factor; VEGF-A, Vascular endothelial growth factor A; VEGFR-2, Vascular endothelial growth factor receptor subtype 2.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available online: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed on 1 December 2014).
2. Grimm, D.; Wehland, M.; Pietsch, J.; Infanger, M.; Bauer, J. Drugs interfering with apoptosis in breast cancer. *Curr. Pharm. Des.* **2011**, *17*, 272–283.
3. Grimm, D.; Bauer, J.; Schönberger, J. Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and its metastases. *Curr. Vasc. Pharmacol.* **2009**, *7*, 347–357.
4. Miklos, G.L. Bevacizumab in neoadjuvant treatment for breast cancer. *N. Engl. J. Med.* **2012**, *366*, 1637–1640.
5. Bear, H.D.; Tang, G.; Rastogi, P.; Geyer, C.E., Jr; Robidoux, A.; Atkins, J.N.; Baez-Diaz, L.; Brufsky, A.M.; Mehta, R.S.; Fehrenbacher, L.; *et al.* Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *N. Engl. J. Med.* **2012**, *366*, 310–320.
6. Fan, F.; Schimming, A.; Jaeger, D.; Podar, K. Targeting the tumor microenvironment: Focus on angiogenesis. *J. Oncol.* **2012**, *2012*, 281261, doi:10.1155/2012/281261.
7. Jelkmann, W. Pitfalls in the measurement of circulating vascular endothelial growth factor. *Clin. Chem.* **2001**, *47*, 617–623.
8. Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. *Nature* **2011**, *473*, 298–307.
9. Claesson-Welsh, L.; Welsh, M. VEGFA and tumour angiogenesis. *J. Intern. Med.* **2013**, *273*, 114–127.
10. Wehland, M.; Bauer, J.; Magnusson, N.E.; Infanger, M.; Grimm, D. Biomarkers for anti-angiogenic therapy in cancer. *Int. J. Mol. Sci.* **2013**, *14*, 9338–9364.
11. Leite de Oliveira, R.; Hamm, A.; Mazzone, M. Growing tumor vessels: More than one way to skin a cat—Implications for angiogenesis targeted cancer therapies. *Mol. Aspects Med.* **2011**, *32*, 71–87.
12. Folkman, J. Tumor angiogenesis: Therapeutic implications. *N. Engl. J. Med.* **1971**, *285*, 1182–1186.
13. Niu, G.; Chen, X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. *Curr. Drug Targets* **2010**, *11*, 1000–1017.
14. Leenders, W.P.; Kusters, B.; de Waal, R.M. Vessel co-option: How tumors obtain blood supply in the absence of sprouting angiogenesis. *Endothelium* **2002**, *9*, 83–87.
15. Donnem, T.; Hu, J.; Ferguson, M.; Adighibe, O.; Snell, C.; Harris, A.L.; Gatter, K.C.; Pezzella, F. Vessel co-option in primary human tumors and metastases: An obstacle to effective anti-angiogenic treatment? *Cancer Med.* **2013**, *2*, 427–436.
16. Ferrara, N. The role of VEGF in the regulation of physiological and pathological angiogenesis. In *Mechanisms of Angiogenesis*; Clauss, M., Breier, G., Eds.; Birkhäuser: Basel, Switzerland, 2005; pp. 209–231.
17. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. *Endocr. Rev. 2004*, 25, 581–611.
18. Grimm, D.; Bauer, J.; Ulbrich, C.; Westphal, K.; Wehland, M.; Infanger, M.; Aleshcheva, G.; Pietsch, J.; Gardi, M.; Beck, M.; *et al.* Different responsiveness of endothelial cells to Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor added to culture media under gravity and simulated microgravity. *Tissue Eng. Part A 2010*, 16, 1559–1573.
19. Infanger, M.; Grosse, J.; Westphal, K.; Leder, A.; Ulbrich, C.; Paul, M.; Grimm, D. Vascular Endothelial Growth Factor induces extracellular matrix proteins and osteopontin in the umbilical artery. *Ann. Vasc. Surg. 2008*, 22, 273–284.
20. Infanger, M.; Faramarzi, S.; Grosse, J.; Kurth, E.; Ulbrich, C.; Bauer, J.; Wehland, M.; Kreutz, R.; Kossmehl, P.; Paul, M.; *et al.* Expression of Vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia-reperfusion injury. *Cardiovasc. Pathol. 2007*, 16, 291–299.
21. Infanger, M.; Shakibaei, M.; Kossmehl, P.; Hollenberg, S.M.; Grosse, J.; Faramarzi, S.; Schulze-Tanzil, G.; Paul, M.; Grimm, D. Intraluminal application of VEGF enhances healing of microvascular anastomosis in a rat model. *J. Vasc. Res. 2005*, 42, 202–213.
22. Grothey, A.; Ellis, L.M. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. *Cancer J. 2008*, 14, 170–177.
23. Miller, K.D.; Chap, L.I.; Holmes, F.A.; Cobleigh, M.A.; Marcom, P.K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B.A.; Reimann, J.D.; Sing, A.P.; *et al.* Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *J. Clin. Oncol. 2005*, 23, 792–799.
24. Mackey, J.; Gelmon, K.; Martin, M.; McCarthy, N.; Pinter, T.; Rupin, M.; Youssoufian, H. TRIO-012: A multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel vs. placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. *Clin. Breast Cancer 2009*, 9, 258–261.
25. Wehland, M.; Bauer, J.; Infanger, M.; Grimm, D. Target-based anti-angiogenic therapy in breast cancer. *Curr. Pharm. Des. 2012*, 18, 4244–4257.
26. Von Minckwitz, G.; Eidtmann, H.; Rezai, M.; Fasching, P.A.; Tesch, H.; Eggemann, H.; Schrader, I.; Kittel, K.; Hanusch, C.; Kreienberg, R.; *et al.* Neoadjuvant chemotherapy and bevacizumab for her2-negative breast cancer. *N. Engl. J. Med. 2012*, 366, 299–309.
27. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab vs. paclitaxel alone for metastatic breast cancer. *N. Engl. J. Med. 2007*, 357, 2666–2676.
30. Refaat, T.; Choi, M.; Gaber, G.; Kiel, K.; Mehta, M.; Gradishar, W.; Small, W., Jr. Markov model and cost-effectiveness analysis of bevacizumab in Her2-negative metastatic breast cancer. *Am. J. Clin. Oncol.* 2014, 37, 480–485.

31. Miles, D.W.; Diéras, V.; Cortés, J.; Duenne, A.A.; Yi, J.; O'Shaughnessy, J. First-line bevacizumab in combination with chemotherapy for Her2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. *Ann. Oncol.* 2013, 24, 2773–2780.

32. Robert, N.J.; Dieras, V.; Glaspy, J.; Brufsky, A.M.; Bondarenko, I.; Lipatov, O.N.; Perez, E.A.; Yardley, D.A.; Chan, S.Y.; Zhou, X.; et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. *J. Clin. Oncol.* 2011, 29, 1252–1260.

33. Gligorov, J.; Doval, D.; Bines, J.; Alba, E.; Cortes, P.; Pierga, J.Y.; Gupta, V.; Costa, R.; Srock, S.; de Ducla, S.; et al. Maintenance capecitabine and bevacizumab vs. bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with Her2-negative metastatic breast cancer (IMelda): A randomised, open-label, phase 3 trial. *Lancet Oncol.* 2014, 15, 1351–1360.

34. Brufsky, A.M.; Hurvitz, S.; Perez, E.; Swamy, R.; Valero, V.; O’Neill, V.; Rugo, H.S. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J. Clin. Oncol.* 2011, 29, 4286–4293.

35. Von Minckwitz, G.; Puglisi, F.; Cortes, J.; Vrdoljak, E.; Marschner, N.; Zielinski, C.; Villanueva, C.; Romieu, G.; Lang, I.; Ciruelos, E.; et al. Bevacizumab plus chemotherapy vs. chemotherapy alone as second-line treatment for patients with Her2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial. *Lancet Oncol.* 2014, 15, 1269–1278.

36. Montero, A.J.; Avancha, K.; Gluck, S.; Lopes, G. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. *Breast Cancer Res. Treat.* 2012, 132, 747–751.

37. Gianni, L.; Romieu, G.H.; Lichinitser, M.; Serrano, S.V.; Mansutti, M.; Pivot, X.; Mariani, P.; Andre, F.; Chan, A.; Lipatov, O.; et al. AVEREL: A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for Her2-positive locally recurrent/metastatic breast cancer. *J. Clin. Oncol.* 2013, 31, 1719–1725.

38. Choueiri, T.K.; Mayer, E.L.; Je, Y.; Rosenberg, J.E.; Nguyen, P.L.; Azzi, G.R.; Bellmunt, J.; Burstein, H.J.; Schutz, F.A. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. *J. Clin. Oncol.* 2011, 29, 632–638.

39. Spratlin, J.L.; Cohen, R.B.; Eadens, M.; Gore, L.; Camidge, D.R.; Diab, S.; Leong, S.; O’Bryant, C.; Chow, L.Q.; Serkova, N.J.; et al. Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. *J. Clin. Oncol.* 2010, 28, 780–787.

40. Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer. Available online: http://clinicaltrials.gov/ct2/show/NCT00703326 (accessed on 1 December 2014).

41. ClinicalTrial.gov. Available online: http://clinicaltrials.gov (accessed on 25 October 2014).
42. Gradishar, W.J. Sorafenib in locally advanced or metastatic breast cancer. *Expert Opin. Investig. Drugs* **2012**, *21*, 1177–1191.
43. Schwartzberg, L.S.; Tauer, K.W.; Hermann, R.C.; Makari-Judson, G.; Isaacs, C.; Beck, J.T.; Kaklamani, V.; Stepanski, E.J.; Rugo, H.S.; Wang, W.; *et al*. Sorafenib or placebo with either gemcitabine or capecitabine in patients with her-2-negative advanced breast cancer that progressed during or after bevacizumab. *Clin. Cancer Res.* **2013**, *19*, 2745–2754.
44. Huober, J.; Fasching, P.A.; Hanusch, C.; Rezai, M.; Eidtmann, H.; Kittel, K.; Hilfrich, J.; Schwedler, K.; Blohmer, J.U.; Tesch, H.; *et al*. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (ec) +/- bevacizumab—Results of the randomised geparquinto study (GBG 44). *Eur. J. Cancer* **2013**, *49*, 2284–2293.
45. Gampenrieder, S.P.; Romeder, F.; Muss, C.; Pircher, M.; Ressler, S.; Rinnerthaler, G.; Bartsch, R.; Sattlberger, C.; Mlineritsch, B.; Greil, R. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: Results from a retrospective matched-pair analysis. *Anticancer Res.* **2014**, *34*, 227–233.
46. Bertolini, F. Response to anti-angiogenesis: An ever changing feature. *Breast* **2011**, *20*, S61–S62.
47. Antoniou, A.; Pharoah, P.D.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; *et al*. Average risks of breast and ovarian cancer associated with brca1 or brca2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. *Am. J. Hum. Genet.* **2003**, *72*, 1117–1130.
48. Mahdi, K.M.; Nassiri, M.R.; Nasiri, K. Hereditary genes and snps associated with breast cancer. *Asian Pac. J. Cancer Prev.* **2013**, *14*, 3403–3409.
49. Nelen, M.R.; Kremer, H.; Konings, I.B.; Schoute, F.; van Essen, A.J.; Koch, R.; Woods, C.G.; Fryns, J.P.; Hamel, B.; Hoefsloot, L.H.; *et al*. Novel PTEN mutations in patients with cowden disease: Absence of clear genotype-phenotype correlations. *Eur. J. Hum. Genet.* **1999**, *7*, 267–273.
50. Schneider, B.P.; Wang, M.; Radovich, M.; Sledge, G.W.; Badve, S.; Thor, A.; Flockhart, D.A.; Hancock, B.; Davidson, N.; Gralow, J.; *et al*. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. *J. Clin. Oncol.* **2008**, *26*, 4672–4678.
51. Miles, D.W.; Chan, A.; Dirix, L.Y.; Cortes, J.; Pivot, X.; Tomczak, P.; Delozier, T.; Sohn, J.H.; Provencher, L.; Puglisi, F.; *et al*. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J. Clin. Oncol.* **2010**, *28*, 3239–3247.
52. Miles, D.W.; de Haas, S.L.; Dirix, L.Y.; Romieu, G.; Chan, A.; Pivot, X.; Tomczak, P.; Provencher, L.; Cortes, J.; Delmar, P.R.; *et al*. Biomarker results from the avado phase 3 trial of first-line bevacizumab plus docetaxel for her2-negative metastatic breast cancer. *Br. J. Cancer* **2013**, *108*, 1052–1060.
53. Keyhani, E.; Muhammadnejad, A.; Behjati, F.; Sirati, F.; Khodadadi, F.; Karimlou, M.; Moghaddam, F.A.; Pazhoomand, R. Angiogenesis markers in breast cancer—Potentially useful tools for priority setting of anti-angiogenic agents. *Asian Pac. J. Cancer Prev.* **2013**, *14*, 7651–7656.
54. Jubb, A.M.; Miller, K.D.; Rugo, H.S.; Harris, A.L.; Chen, D.; Reiman, J.D.; Cobleigh, M.A.; Schmidt, M.; Langmuir, V.K.; Hillan, K.J.; et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. *Clin. Cancer Res.* 2011, 17, 372–381.

55. Ohtsu, A.; Shah, M.A.; van Cutsem, E.; Rha, S.Y.; Sawaki, A.; Park, S.R.; Lim, H.Y.; Yamada, Y.; Wu, J.; Langer, B.; et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. *J. Clin. Oncol.* 2011, 29, 3968–3976.

56. Saltz, L.B.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.S.; Rivera, F.; et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. *J. Clin. Oncol.* 2008, 26, 2013–2019.

57. Errico, A. Combining bevacizumab with chemotherapy—From maintenance to second-line treatment. *Nat. Rev. Clin. Oncol.* 2014, doi:10.1038/nrclinonc.2014.179.

58. Pepin, F.; Bertos, N.; Laferriere, J.; Sadekova, S.; Souleimanova, M.; Zhao, H.; Finak, G.; Meterissian, S.; Hallett, M.T.; Park, M. Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes. *Breast Cancer Res.* 2012, 14, doi:10.1186/bcr3246.

59. Wang, N.; Wang, Z.Y.; Mo, S.L.; Loo, T.Y.; Wang, D.M.; Luo, H.B.; Yang, D.P.; Chen, Y.L.; Shen, J.G.; Chen, J.P. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via vegfr-2 signaling pathway in breast cancer. *Breast Cancer Res. Treat.* 2012, 134, 943–955.

60. Purdue, M.P.; Johansson, M.; Zelenika, D.; Toro, J.R.; Scelo, G.; Moore, L.E.; Prokhortchouk, E.; Wu, X.; Kiemeney, L.A.; Gaborieau, V.; et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. *Nat. Genet.* 2011, 43, 60–65.

61. Sledge, G.W. Anti-vascular endothelial growth factor therapy in breast cancer: Game over? *J. Clin. Oncol.* 2014, doi:10.1200/JCO.2014.58.1298.

62. De Luca, A.; Lamura, L.; Gallo, M.; Maffia, V.; Normanno, N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. *J. Cell Biochem.* 2012, 113, 3363–3370.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).